查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1571451

原發性免疫力缺乏症候群市場規模、佔有率和趨勢分析報告：按疾病、治療方法、地區和細分市場預測，2024-2030

Primary Immunodeficiency Disorders Market Size, Share & Trends Analysis Report By Disease (Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders), By Treatment, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

原發性免疫力缺乏症候群市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年，全球原發性免疫力缺乏症候群市場規模將達111.4億美元。

預計2024年至2030年複合年成長率為6.4%。由於幾個關鍵因素，該行業正在經歷顯著成長。遺傳病患病率的不斷上升、醫療保健專業人員意識的提高以及診斷和治療技術的進步對於該行業的擴張至關重要。

2022 年 12 月在《新英格蘭醫學日誌》上發表的一項研究強調了基因治療治療 Artemis 缺陷型嚴重聯合免疫力缺乏(ART-SCID) 的成功。透過將 DCLRE1C 基因的健康拷貝添加到患者的幹細胞中，這種治療方法有效地恢復了 T 細胞和 B 細胞的功能。這項針對 10 名嬰兒進行的研究表明，與傳統治療相比，免疫系統顯著恢復，併發症也更少。儘管研究人員對這種治療方法的潛力持樂觀態度，但仍需要進一步的長期研究和廣泛的臨床試驗來考慮 FDA 的核准及其對不同人群的適用性。 Artemis 缺陷型 SCID 基因療法的成功證明了對先前難以治療的疾病的有效治療，並支持了產業發展。這項進步將推動對基因治療解決方案和治療創新的需求。這項研究的積極成果可能會導致投資增加、廣泛採用和新治療方法的開發，從而擴大先進治療方法的行業。

此外，幾種藥物的成功凸顯了類似創新的潛力，促進了產業擴張並鼓勵該領域專業治療方法的進一步開發。例如，2023年3月，Pharming Group的reniolisib（Joenha）被FDA核准作為首個治療12歲及以上病患的活化磷酸肌醇3激酶Delta症候群（APDS）的藥物。這項核准是在一項為期 12 週的試驗之後進行的，該試驗表明，與安慰劑相比，reniolisib 減少了淋巴結大小，並將初始 B 細胞計數提高了 37%。基因療法的進步和雷尼奧利西等新治療方法的核准正在擴大該行業。這些創新代表了以前難以治療的疾病的有效解決方案，並推動了對該領域的投資和興趣的增加。這些治療方法的成功增強了市場信心並鼓勵專門治療方法的進一步發展。隨著研究的進步和新治療方法的出現，先進的免疫力缺乏治療市場預計將繼續強勁成長，最終使患者和醫療保健提供者受益。

原發性免疫力缺乏症候群市場報告亮點

  • 按地區分類，北美市場佔有率最大，2023年為45.39%。該市場是由該地區強大的醫療基礎設施、高患病率和積極的政府舉措推動的。
  • 依疾病分，抗體缺乏比例最大，2023年為52.62%。這種成長是由於高盛行率、對醫療保健的重大影響以及針對性治療方法的開發。意識的提高和先進的診斷技術也提高了我們在行業中的影響力。
  • 依治療方法，免疫球蛋白替代療法所佔佔有率最大，2023年佔63.18%。對有效治療的高需求、治療的進步以及對持續治療的迫切需求正在促成巨大的市場佔有率。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第 3 章原發性免疫力缺乏症候群市場變數、趨勢、範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 原發性免疫力缺乏症候群市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章原發性免疫力缺乏症候群市場：疾病估計與趨勢分析

  • 細分儀表板
  • 原發性免疫力缺乏症候群市場：疾病波動分析
  • 原發性免疫力缺乏症候群市場：依疾病分類的前景
  • 2018-2030 年市場規模與預測/趨勢分析
  • 抗體缺乏
  • 細胞介導的免疫力缺乏
  • 先天性免疫疾病
  • 其他

第5章原發性免疫力缺乏缺陷症候群市場：治療方法估計和趨勢分析

  • 細分儀表板
  • 原發性免疫力缺乏症候群市場：治療方法變異分析
  • 原發性免疫力缺乏症候群市場：按治療方法的前景
  • 2018-2030 年市場規模與預測/趨勢分析
  • 免疫球蛋白替代療法
  • 抗生素治療
  • 幹細胞/骨髓移植
  • 基因治療
  • 其他

第6章原發性免疫力缺乏缺陷症候群市場：區域估計與趨勢分析

  • 區域儀表板
  • 原發性免疫力缺乏症候群市場：區域變化分析
  • 原發性免疫力缺乏症候群市場：區域展望
  • 2018-2030 年市場規模與預測/趨勢分析
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
    • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 挪威
    • 瑞典
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭格局

  • 市場參與企業分類
  • 主要企業簡介
    • Baxter International, Inc.
    • CSL Behring LLC
    • Takeda Pharmaceutical Company Limited
    • Octapharma
    • Biotest AG
    • Grifols, SA
    • Kedrion Biopharma Inc
    • Bio Products Laboratory Ltd
    • LFB SA
    • ADMA Biologics, Inc.
    • Abbott Laboratories
    • Astellas Pharma Inc.
Product Code: GVR-4-68040-444-4

Primary Immunodeficiency Disorders Market Growth & Trends:

The global primary immunodeficiency disorders market size is expected to reach USD 11.14 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 6.4% from 2024 to 2030. The industry is experiencing significant growth, driven by multiple key factors. Rising incidences of genetic disorders, increased awareness among healthcare professionals, and advancements in diagnostic and therapeutic technologies are pivotal in expanding the industry.

A study published in The New England Journal of Medicine in December 2022 highlights the success of gene therapy for Artemis-deficient severe combined immunodeficiency (ART-SCID). By adding a healthy copy of the DCLRE1C gene to patients' stem cells, this therapy effectively restored T and B cell function. The study, involving 10 infants, showed significant immune recovery and reduced complications compared to traditional treatments. Researchers are optimistic about the therapy's potential, though further long-term studies and broader trials are needed for FDA approval and to explore its applicability in diverse populations. The successful gene therapy for Artemis-deficient SCID boosts industry growth by demonstrating effective treatment for previously difficult-to-treat conditions. This advancement drives demand for gene therapy solutions and innovations in treatments. The positive outcomes from this study potentially leading to increased investment, broader adoption, and the development of new therapies, thereby expanding the industry for advanced treatments.

Moreover, several drug's success highlights the potential for similar innovations, fostering industry expansion and encouraging further development of specialized therapies in the sector. For instance, in March 2023, Pharming Group leniolisib (Joenja) approved by the FDA as the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) in patients aged 12 and older. The approval follows a 12-week study demonstrating that leniolisib reduced lymph node size and improved naive B cell counts by 37% compared to placebo. The industry is expanding due to advancements in gene therapy and the approval of new treatments such as leniolisib. These innovations demonstrate effective solutions for previously difficult-to-treat conditions, driving increased investment and interest in the sector. The success ofthese therapies boosts market confidence and encourages further development of specialized treatments. As research progresses and new therapies emerge, the market for advanced immunodeficiency treatments is expected to continue its robust growth, ultimately benefiting patients and healthcare providers alike.

Primary Immunodeficiency Disorders Market Report Highlights:

  • Based on region, North America accounted for largest market share of 45.39% in 2023. The market is driven by robust healthcare infrastructure, high prevalence, and proactive government initiatives in the region.
  • Based on disease, antibody deficiency segment accounted for the largest share of 52.62% in disease segment in 2023. The growth can be attributed to its high prevalence, significant healthcare impact, and the development of targeted treatments. Increased awareness and advanced diagnostics also contribute to its substantial presence in the industry.
  • Based on product, the immunoglobulin replacement therapy segment holds the largest share in the market accounted for 63.18% in 2023 owing to its essential role in managing antibody deficiencies. High demand for effective treatment, advancements in therapy, and the critical need for ongoing care contribute to its substantial market share.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Disease
    • 1.2.2. Treatment
    • 1.2.3. Regional Scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Disease outlook
    • 2.2.2. Treatment outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. Primary Immunodeficiency Disorders Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Primary Immunodeficiency Disorders Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Primary Immunodeficiency Disorders Market: Disease Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Primary Immunodeficiency Disorders Market: Disease Movement Analysis
  • 4.3. Primary Immunodeficiency Disorders Market by Disease Outlook (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Antibody Deficiency
    • 4.5.1. Antibody Deficiency Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Cellular Immunodeficiency
    • 4.6.1. Cellular Immunodeficiency Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Innate Immune Disorders
    • 4.7.1. Innate Immune Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Primary Immunodeficiency Disorders Market: Treatment Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Primary Immunodeficiency Disorders Market: Treatment Movement Analysis
  • 5.3. Primary Immunodeficiency Disorders Market by Treatment Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Immunoglobulin Replacement Therapy
    • 5.5.1. Immunoglobulin Replacement Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Antibiotic Therapy
    • 5.6.1. Antibiotic Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Stem Cell/Bone Marrow Transplantation
    • 5.7.1. Stem Cell/Bone Marrow Transplantation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. Gene Therapy
    • 5.8.1. Gene Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.9. Others
    • 5.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Primary Immunodeficiency Disorders Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Dashboard
  • 6.2. Regional Primary Immunodeficiency Disorders Market movement analysis
  • 6.3. Primary Immunodeficiency Disorders Market: Regional Estimates & Trend Analysis by Disease, Biomaterial & End-use
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.5. North America
    • 6.5.1. North America Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. U.S.
      • 6.5.2.1. U.S. Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Canada
      • 6.5.3.1. Canada Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. Mexico
      • 6.5.4.1. Mexico Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Europe
    • 6.5.6. Europe Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. UK
      • 6.5.7.1. UK Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Germany
      • 6.5.8.1. Germany Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. France
      • 6.5.9.1. France Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.10. Italy
      • 6.5.10.1. Italy Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.11. Spain
      • 6.5.11.1. Spain Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.12. Denmark
      • 6.5.12.1. Denmark Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.13. Norway
      • 6.5.13.1. Norway Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.14. Sweden
      • 6.5.14.1. Sweden Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Japan Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. China Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. India Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. South Korea
      • 6.6.5.1. South Korea Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. Australia
      • 6.6.6.1. Australia Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Thailand Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Brazil Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Argentina Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Middle East & Africa
    • 6.8.1. Middle East & Africa Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. South Africa Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Saudi Arabia Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. UAE Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Kuwait Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Market Participant Categorization
  • 7.2. Key Company Profiles
    • 7.2.1. Baxter International, Inc.
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Disease benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. CSL Behring LLC
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Takeda Pharmaceutical Company Limited
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Octapharma
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. Biotest AG
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Grifols, S.A.
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Kedrion Biopharma Inc
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. Bio Products Laboratory Ltd
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. LFB S.A
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. ADMA Biologics, Inc.
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives
    • 7.2.11. Abbott Laboratories
      • 7.2.11.1. Company overview
      • 7.2.11.2. Financial performance
      • 7.2.11.3. Product benchmarking
      • 7.2.11.4. Strategic initiatives
    • 7.2.12. Astellas Pharma Inc.
      • 7.2.12.1. Company overview
      • 7.2.12.2. Financial performance
      • 7.2.12.3. Product benchmarking
      • 7.2.12.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 4 Global primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 5 North America primary immunodeficiency disorders market, by region, 2018 - 2030 (USD Million)
  • Table 6 North America primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 7 North America primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 8 U.S primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 9 U.S primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 10 Canada primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 11 Canada primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 12 Mexico primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 13 Mexico primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 14 Europe primary immunodeficiency disorders market, by country, 2018 - 2030 (USD Million)
  • Table 15 Europe primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 16 Europe primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 17 UK primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 18 UK primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 19 Germany primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 20 Germany primary immunodeficiency disorders market, by treatment 2018 - 2030 (USD Million)
  • Table 21 France primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 22 France primary immunodeficiency disorders market, by treatment 2018 - 2030 (USD Million)
  • Table 23 Italy primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 24 Italy primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 25 Spain primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 26 Spain primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 27 Denmark primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 28 Denmark primary immunodeficiency disorders market, by treatment 2018 - 2030 (USD Million)
  • Table 29 Norway primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 30 Norway primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 31 Sweden primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 32 Sweden primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific primary immunodeficiency disorders market, by country, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 36 Japan primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 37 Japan primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 38 China primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 39 China primary immunodeficiency disorders market, by treatment 2018 - 2030 (USD Million)
  • Table 40 India primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 41 India primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 42 Australia primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 43 Australia primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 44 South Korea primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 45 South Korea primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 46 Thailand primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 47 Thailand primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 48 Latin America primary immunodeficiency disorders market, by country, 2018 - 2030 (USD Million)
  • Table 49 Latin America primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 50 Latin America primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 51 Brazil primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 52 Brazil primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 53 Argentina primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 54 Argentina primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 55 Middle East & Africa primary immunodeficiency disorders market, by country, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 58 South Africa primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 59 South Africa primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 60 Saudi Arabia primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 62 UAE primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 63 UAE primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 64 Kuwait primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 65 Kuwait primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information procurement
  • Fig. 2 Primary research pattern
  • Fig. 3 Market research approaches
  • Fig. 4 Value chain-based sizing & forecasting
  • Fig. 5 Market formulation & validation
  • Fig. 6 Primary immunodeficiency disorders market segmentation
  • Fig. 7 Market driver analysis (current & future impact)
  • Fig. 8 Market restraint analysis (current & future impact)
  • Fig. 9 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 10 Porter's five forces analysis
  • Fig. 11 Primary immunodeficiency disorders market, disease outlook key takeaways, (USD Million)
  • Fig. 12 Primary immunodeficiency disorders market: disease movement analysis, 2023 & 2030 (USD Million)
  • Fig. 13 Antibody deficiency market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 14 Cellular immunodeficiency market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 15 Innate immune disorders market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 16 Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 17 Primary immunodeficiency disorders market, treatment outlook key takeaways, (USD Million)
  • Fig. 18 Primary immunodeficiency disorders market: treatment movement analysis, 2023 & 2030 (USD Million)
  • Fig. 19 Immunoglobulin replacement therapy market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Antibiotic therapy market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Stem cell/ bone marrow transplantation market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Gene therapy market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Primary immunodeficiency disorders market: regional key takeaways (USD Million)
  • Fig. 25 Primary immunodeficiency disorders market: regional outlook, 2023 & 2030 (USD Million)
  • Fig. 26 North America Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 US Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Canada Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Mexico Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Europe Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 UK Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Germany Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 France Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Spain Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Italy Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Norway Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Denmark Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Sweden Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Asia Pacific Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 China Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Japan Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 India Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 South Korea Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Australia Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Thailand Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Latin America Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Brazil Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Argentina Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Middle East and Africa Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 South Africa Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Saudi Arabia Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 UAE Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Kuwait Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 List of key emerging company's/technology disruptors/innovators